Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Warning Letters Special Report: A Focus On Sterility Risks From Water Systems, Open Cleanrooms

Executive Summary

A B. cepacia contamination recurrence led the US FDA to double down on sterility assurance of water systems in 2022, a trend likely to continue, Part 7 of our series finds. Open cleanroom contamination continued to drive warning letters as Annex 1 policy revision adds incentives to separate workers from injectable drug products with access barriers or isolators.

You may also be interested in...

Generic Drug Facility Post-Warning Letter Meetings Likely Will Hinge On ‘Reasonable Progress’

Facility owners should ensure they are ready when asking for the meeting on deficiency remediation because only two requests are allowed per warning letter.

India's Top Brass Talks Of Repaying IP Debt, Equity For Academia, ESG Goals

The heads of Sun, Cipla, Zydus, Lupin and Dr. Reddy's discuss moves to drive innovation including equity stakes for academia in research ventures as India approves an apex body to promote, fund and mentor research. Ways to progress ESG goals were also discussed at the IPA summit.

Warning Letters Special Report: Pandemic Drove Focused Inspections, Alternative Approaches

In the first part of our in-depth series, the Pink Sheet outlines how 2022 warning letters reflected agency’s efforts to overcome COVID-19 travel restrictions. As pandemic abates, a new, less inspection-intensive normal could emerge.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts